RO

Roche

Every trial this sponsor leads in the registry, and everything it has published.

2,269All trials
Recruiting89
Recruited135
Not yet recruiting6
By invitation1
Completed1,749
Stopped283
Other6

231 active · 10% of this sponsor’s registry footprint

Oncology107 trials
Neurology43 trials
Immunology & Inflammation21 trials
Ophthalmology13 trials
Metabolic/Endocrine/Nutrition11 trials
Haematology9 trials
Renal & Urology4 trials
Gastroenterology & Hepatology3 trials

Not shown above: 3 Phase 1 healthy-volunteer trials and 9 trials whose condition matched no therapy area.

Trials by phase

Phase 1750
Phase 2576
Phase 3657
Phase 4234
Unphased52

Pipeline by phase · 86 drugs in active development

Phase 3 · 30 drugs

Atezolizumab14 trials · 1 recruitingest. Oct 2026
Afimkibart (RO7790121)13 trials · 9 recruitingest. Sept 2026
Inavolisib13 trials · 9 recruitingest. Nov 2026
Obinutuzumab9 trials · 4 recruitingest. Jan 2027
Cevostamab8 trials · 5 recruitingest. Nov 2026
Giredestrant (GDC-9545)8 trials · 2 recruitingest. Jul 2027
Mosunetuzumab7 trials · 2 recruitingest. Feb 2028
Alectinib5 trials · 1 recruitingest. Nov 2026

Phase 2 · 16 drugs

Emugrobart (RO7204239)4 trialsest. Oct 2026
RO77950814 trials · 1 recruitingest. Nov 2026
Tobemstomig (RO7247669)4 trialsest. Oct 2026
Autogene cevumeran2 trialsest. Nov 2027
OpRegen2 trials · 1 recruitingest. Mar 2031
RO77719502 trials · 1 recruitingest. Aug 2027
DONQ521 trial · 1 recruitingest. Jun 2027

Phase 1 · 34 drugs

RAY1212 trials · 1 recruitingest. Mar 2027
ALPS121 trial · 1 recruitingest. Sept 2028
AUBE001 trial · 1 recruitingest. Dec 2029
Belvarafenib1 trialest. Dec 2026
Englumafusp alfa1 trialest. Mar 2027
Enzelkitug1 trialest. Jul 2028
ERY9741 trial
GDC-12611 trial · 1 recruitingest. Nov 2027

Phase 4 · 6 drugs

Ocrelizumab13 trials · 2 recruitingest. Sept 2026
Risdiplam4 trials · 2 recruitingest. Oct 2026
Emicizumab3 trials · 1 recruitingest. Apr 2027
Faricimab2 trialsest. Oct 2026
LUCENTIS (Ranibizumab Injection)1 trial · 1 recruitingest. Jul 2027
Tumor Tissue and Blood Draw1 trial · 1 recruitingest. Dec 2027

Not counted above: 2 combination backbones (established drugs used alongside the assets) and 1 unphased intervention.

Active trials only, code names and brands merged. 1,749 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 7 of 10 curated

Breast cancer (Oncology)25 trials · 11 recruiting · 10 drugs0.8% of landscape
Non-small cell lung cancer (Oncology)13 trials · 3 recruiting · 6 drugs0.9% of landscape
Multiple myeloma (Oncology)9 trials · 5 recruiting · 3 drugs1.2% of landscape
Alzheimer's disease (Neurology)5 trials · 1 recruiting · 3 drugs1.3% of landscape
Type 2 diabetes (Endocrinology)5 trials · 2 recruiting · 4 drugs0.5% of landscape
Atopic dermatitis (Dermatology)2 trials · 1 recruiting · 1 drug1.1% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)1 trial · 1 recruiting · 1 drug0.6% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon